Small Molecule Decoys of Aggregation for Elimination of Aβ-Peptide Toxicity
暂无分享,去创建一个
[1] J. Baell,et al. Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers , 2021, Science Translational Medicine.
[2] A. K. Dasmahapatra,et al. Destabilization of the Alzheimer’s amyloid-β peptide by a proline-rich β-sheet breaker peptide: a molecular dynamics simulation study , 2021, Journal of Molecular Modeling.
[3] G. Petsko,et al. Endosomal recycling reconciles the Alzheimer’s disease paradox , 2020, Science Translational Medicine.
[4] S. Schreiber,et al. Unifying principles of bifunctional, proximity-inducing small molecules , 2020, Nature Chemical Biology.
[5] J. Changeux,et al. A strategy for designing allosteric modulators of transcription factor dimerization , 2020, Proceedings of the National Academy of Sciences.
[6] D. Holtzman,et al. Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.
[7] P. Genevaux,et al. (Bio)Chemical strategies to modulate amyloid-β self-assembly. , 2019, ACS chemical neuroscience.
[8] Michele Vendruscolo,et al. Different soluble aggregates of Aβ42 can give rise to cellular toxicity through different mechanisms , 2019, Nature Communications.
[9] Gwendolyn E. Kaeser,et al. Somatic APP gene recombination in Alzheimer’s disease and normal neurons , 2018, Nature.
[10] S. Prusiner,et al. Structural heterogeneity and intersubject variability of Aβ in familial and sporadic Alzheimer’s disease , 2018, Proceedings of the National Academy of Sciences.
[11] Nick C Fox,et al. Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer’s disease , 2017, Proceedings of the National Academy of Sciences.
[12] John Collinge,et al. Structural Variation in Amyloid-β Fibrils from Alzheimer’s Disease Clinical Subtypes , 2016, Nature.
[13] S. Pastorino,et al. Multiple spatially related pharmacophores define small molecule inhibitors of OLIG2 in glioblastoma , 2015, Oncotarget.
[14] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[15] A. Gräslund,et al. Heterogeneity and Turnover of Intermediates during Amyloid-β (Aβ) Peptide Aggregation Studied by Fluorescence Correlation Spectroscopy. , 2015, Biochemistry.
[16] L. Tjernberg,et al. Highly Sensitive FRET-FCS Detects Amyloid β-Peptide Oligomers in Solution at Physiological Concentrations. , 2015, Analytical chemistry.
[17] Jun Hu,et al. Tunable assembly of amyloid-forming peptides into nanosheets as a retrovirus carrier , 2015, Proceedings of the National Academy of Sciences.
[18] Giovanni Dietler,et al. Influence of the β-sheet content on the mechanical properties of aggregates during amyloid fibrillization. , 2015, Angewandte Chemie.
[19] S. Radford,et al. Screening and classifying small molecule inhibitors of amyloid formation using ion mobility spectrometry-mass spectrometry , 2014, Nature Chemistry.
[20] Charles D. Schwieters,et al. Molecular Structure of β-Amyloid Fibrils in Alzheimer’s Disease Brain Tissue , 2013, Cell.
[21] E. O’Hare,et al. Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity , 2012, British journal of pharmacology.
[22] I. Tsigelny,et al. Elucidation of common pharmacophores from analysis of targeted metabolites transported by the multispecific drug transporter-Organic anion transporter1 (Oat1). , 2011, Bioorganic & medicinal chemistry.
[23] M. Hecht,et al. Small molecule microarrays enable the discovery of compounds that bind the Alzheimer's Aβ peptide and reduce its cytotoxicity. , 2010, Journal of the American Chemical Society.
[24] Richard W. Clarke,et al. Direct characterization of amyloidogenic oligomers by single-molecule fluorescence , 2008, Proceedings of the National Academy of Sciences.
[25] R. Wetzel,et al. Polymorphism in the intermediates and products of amyloid assembly. , 2007, Current opinion in structural biology.
[26] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[27] E. Wahle,et al. The nuclear poly(A) binding protein, PABP2, forms an oligomeric particle covering the length of the poly(A) tail. , 2000, Journal of molecular biology.
[28] J. Feeney,et al. Binding of flexible ligands to macromolecules , 1975, Nature.